Jazz PharmaceuticalsJAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $17M | Put options by funds: $7.36M
65% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 55
13% more capital invested
Capital invested by funds: $6.42B [Q3] → $7.26B (+$843M) [Q4]
11% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 10 (+1) [Q4]
7% more funds holding
Funds holding: 470 [Q3] → 501 (+31) [Q4]
4.23% more ownership
Funds ownership: 93.38% [Q3] → 97.61% (+4.23%) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 168
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Needham Ami Fadia 13% 1-year accuracy 22 / 164 met price target | 104%upside $210 | Buy Reiterated | 10 Apr 2025 |
HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 24 / 50 met price target | 111%upside $217 | Buy Maintained | 10 Mar 2025 |
Morgan Stanley Jeffrey Hung 8% 1-year accuracy 2 / 26 met price target | 78%upside $183 | Overweight Assumed | 7 Mar 2025 |
UBS Ashwani Verma 5% 1-year accuracy 1 / 19 met price target | 74%upside $179 | Buy Upgraded | 7 Mar 2025 |
Truist Securities Gregory Fraser 0% 1-year accuracy 0 / 2 met price target | 124%upside $230 | Buy Maintained | 6 Mar 2025 |
Financial journalist opinion
Based on 12 articles about JAZZ published over the past 30 days
